Payment overview · 2025
General Payments
$360.19
21 reported records · 13 companies
Healthcare provider profile · identity verified
Katherine Kiger, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · ATHENS, OH · NPI 1790013720
Verified facts
What the public records show
CMS Open Payments records show Katherine Kiger, D.O. received $360.19 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.06 | 19.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.67 | 13.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.41 | 9.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.08 | 9.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.82 | 9.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.56 | 6.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.84 | 5.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.52 | 5.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.22 | 5.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.95 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.61 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.77 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.68 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $360.19 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.31 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $47.67 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $47.67 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.82 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 85 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 580 | 70 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 508 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 107 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 347 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 96 |
| Omeprazole | Omeprazole | 320 | 89 |
| Alprazolam | Alprazolam | 299 | 43 |
| Gabapentin | Gabapentin | 292 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 72 |
| Oxycodone Hcl | Oxycodone Hcl | 231 | 26 |
| Lisinopril | Lisinopril | 230 | 64 |
| Montelukast Sodium | Montelukast Sodium | 227 | 59 |
| Potassium Chloride | Potassium Chloride | 209 | 56 |
| Losartan Potassium | Losartan Potassium | 197 | 51 |
| Furosemide | Furosemide | 192 | 59 |
| Metformin Hcl Er | Metformin Hcl | 190 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 47 |
| Prednisone | Prednisone | 181 | 75 |
| Lorazepam | Lorazepam | 170 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 46 |
| Ondansetron Odt | Ondansetron | 134 | 33 |
| Bupropion Xl | Bupropion Hcl | 133 | 40 |
| Fluconazole | Fluconazole | 129 | 64 |
| Trazodone Hcl | Trazodone Hcl | 127 | 34 |
| Simvastatin | Simvastatin | 126 | 37 |
| Tramadol Hcl | Tramadol Hcl | 126 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 32 |
| Famotidine | Famotidine | 110 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 30 |
| Metformin Hcl | Metformin Hcl | 96 | 30 |
| Clonazepam | Clonazepam | 95 | 16 |
| Ibuprofen | Ibuprofen | 94 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 32 |
| Sertraline Hcl | Sertraline Hcl | 86 | 20 |
| Eliquis | Apixaban | 85 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 17 |
| Allopurinol | Allopurinol | 82 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 82 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 22 |
| Meloxicam | Meloxicam | 78 | 23 |
| Diazepam | Diazepam | 77 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 24 |
| Estradiol | Estradiol | 73 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 20 |
| Valsartan | Valsartan | 70 | 20 |
| Cefdinir | Cefdinir | 66 | 41 |
| Ozempic | Semaglutide | 65 | 16 |
| Carvedilol | Carvedilol | 64 | 17 |
| Synthroid | Levothyroxine Sodium | 63 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 58 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | suppressed |
| Glipizide Er | Glipizide | 56 | 14 |
| Farxiga | Dapagliflozin Propanediol | 55 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 14 |
| Buspirone Hcl | Buspirone Hcl | 52 | 16 |
| Celecoxib | Celecoxib | 51 | 13 |
| Nystatin | Nystatin | 51 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 17 |
| Azithromycin | Azithromycin | 50 | 28 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Glimepiride | Glimepiride | 47 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 12 |
| Spironolactone | Spironolactone | 38 | 13 |
| Pregabalin | Pregabalin | 36 | 13 |
| Amoxicillin | Amoxicillin | 35 | suppressed |
| Baclofen | Baclofen | 35 | 15 |
| Linzess | Linaclotide | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | 15 |
| Ketoconazole | Ketoconazole | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 23 |
| Clonidine Hcl | Clonidine Hcl | 33 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 33 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 11 |
| Cephalexin | Cephalexin | 31 | 26 |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 11 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 13 |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Topiramate | Topiramate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Symlinpen 60 | Pramlintide Acetate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $360.19 · 21 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, CREON, ELIQUIS, FARXIGA, Jornay PM, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, TRELEGY ELLIPTA, VOQUEZNA, VYEPTI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error